A Study to Learn About the Safety and Effects of the Study Drug PRX-102 in Children and Adolescents With Fabry Disease

Recruiting

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(12 sites)

United States

Phoenix Children's, Phoenix, Arizona

Emory Genetics Clinical Trials Center, Atlanta, Georgia

University of Iowa, Iowa City, Iowa

Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio

University of Utah, Salt Lake City, Utah

Lysosomal and Rare Disorders Research and Treatment Center Inc, Fairfax, Virginia

Austria

UK für Kinder- und Jugendheilkunde der PMU Salzburg, Salzburg

France

Centre Hospitalier Universitaire (CHU) de Bordeaux - Groupe Hospitalier Pellegrin, Bordeaux

Hopital Arnaud de Villeneuve, Montpellier

Norway

Haukeland Universitetssjukehus, Bergen

Spain

Hospital Clinico Universitario De Santiago De Compostela, Santiago de Compostela

United Kingdom

Great Ormond Street Hospital for Children NHS Foundation Trust, London